🇺🇸 FDA
Patent

US 8927576

HCV inhibitor and therapeutic agent combinations

granted A61PA61P31/14

Quick answer

US patent 8927576 (HCV inhibitor and therapeutic agent combinations) held by PTC THERAPEUTICS, INC. expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61P, A61P31/14